09-11, 07:00–07:30 (Europe/Istanbul), Head & Neck Surgery 1
Lecture Objectives By the end of this session, participants will be able to:
Identify recent updates in the surgical and non-surgical management of salivary gland tumors.
Evaluate the clinical impact of novel therapies, including molecularly targeted agents and immunotherapy.
Apply evidence-based approaches to complex and recurrent salivary gland tumors.
Understand the potential of emerging technologies and personalized medicine in shaping future treatment pathways.
Lecture Outline
Overview & Epidemiology
Classification and incidence of benign and malignant salivary gland tumors
Diagnostic challenges and heterogeneity in presentation
Surgical Management Updates
Advances in minimally invasive and nerve-sparing techniques
Reconsidering elective neck dissection and strategies for margin control
Approaches to salvage and revision surgeries
Adjuvant and Definitive Radiotherapy
Modern techniques: IMRT, proton therapy, and adaptive radiotherapy
Evidence-based indications and outcomes
Novel Systemic Therapies
Targeted therapies: androgen blockade in salivary duct carcinoma, HER2 and NTRK inhibitors
Immunotherapy developments: checkpoint inhibitors and PD-L1 targeting
Integration of molecular profiling in personalized treatment algorithms
Emerging and Experimental Approaches
Innovations in gland-sparing radiotherapy
Use of AI, real-time imaging, and navigation in complex surgeries
Ongoing clinical trials and promising investigational strategies
Case-Based Discussions
Practical applications of evolving therapies
Management of advanced, rare, or recurrent tumor types
Summary & Practical Takeaways
Key updates ready for clinical practice
Guidance on translating global evidence to local resource settings
Learning Outcomes
Be updated on current treatment strategies for salivary gland tumors
Recognize the role of targeted and immune-based therapies in specific subtypes
Understand how to integrate molecular and imaging advances into multidisciplinary care
Adapt evidence-based innovations to regional practice environments
Selected References
Bell D, Hanna EY. Curr Oncol Rep. 2021;23(5):57.
Laurie SA, et al. Lancet Oncol. 2011;12(8):815–824.
Coca-Pelaz A, et al. CA Cancer J Clin. 2021;71(4):304–319.
Fushimi C, et al. Cancers. 2022;14(11):2591.
Dillon PM, et al. Head Neck. 2016;38(4):620–627.
El-Naggar AK, et al. WHO Classification of Head and Neck Tumours, 4th ed. IARC, 2017.
Chintakuntlawar AV, et al. Cancers Head Neck. 2016;1:11.
Chau NG, et al. J Clin Oncol. 2016;34(15_suppl):6011.
Al-Zaher N, et al. Int J Otolaryngol. 2011:872812.
Tanvetyanon T, et al. Arch Otolaryngol Head Neck Surg. 2009;135(7):687–692.
The aim of this proposal is to offer a structured, evidence-based session that addresses the complexity and evolving landscape of salivary gland neoplasm management. With recent advances in molecular diagnostics, targeted therapy, and radiotherapeutic technologies, it is essential for practicing otolaryngologists and head and neck surgeons to remain updated. This session intends to bridge the gap between emerging scientific evidence and clinical practice by equipping attendees with applicable knowledge and tools for improved patient outcomes.
An Associate Professor of Otolaryngology, Dr. Dundar joined Texas Tech Physicians in September 2019. Dr. Dundar completed his medical school education at Hacettepe University in 2007 and completed his otolaryngology residency in Yildirim Beyazit Training and Research Hospital in 2012. Dr. Dundar completed his fellowship in head and neck surgical oncology and microvascular reconstructive surgery from Wayne State University. Dr. Dundar specializes in all aspects of head and neck oncology, including cutaneous malignancies, salivary gland cancers, thyroid cancers, mucosal head and neck cancers. He also performs complex microvascular reconstruction of the head and neck as well as transoral robotic surgery.